ajanta pharma limited

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067. INDIA
Tel.: (+91) 22 6606 1000
Fax : (+91) 22 6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

30th April, 2011

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001.

Dear Sir,

Re: Clause 41
Scrip Code: BSE – AJANTAPH 532331
NSE – AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Audited Financial Results for the year ended 31st March, 2011 duly signed by the Vice-Chairman. These results were approved by the Board of Directors at their Meeting held on Saturday, 30th April, 2011.

We are pleased to inform that the Board of Directors have also recommended the dividend @ Rs. 5/- per share, subject to the approval of the shareholders at the ensuing Annual General Meeting to be held on 8th July, 2011.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**

NIKHIL BHATT
G.M. - Legal &
Company Secretary

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Audited Financial Results for the year ended 31st March, 2011

₹ in Lacs

Particulars	Standalone Results				Consolidated Results	
	3 months ended		Accounting Year ended		Accounting Year ended	
	31/03/2011	31/03/2010	31/03/2011	31/03/2010	31/03/2011	31/03/2010
	Unaudited		Audited		Audited	
1. Net Sales/Income from Operations	**12,584.77**	**10,811.53**	**45,714.56**	**38,189.75**	**50,487.17**	**40,914.25**
2. Expenditure						
a. (Increase)/decrease in stock in trade and work in progress	(147.64)	1,361.86	537.37	1,630.53	459.63	713.28
b. Consumption of raw & packing materials	3,987.03	3,357.46	14,319.53	11,227.29	14,789.94	11,386.18
c. Purchase of traded goods	696.85	383.14	2,396.01	2,058.34	2,040.43	1,878.39
d. Employees cost	1,713.80	1,154.55	5,909.93	4,452.08	6,373.77	4,778.93
e. Depreciation	654.55	617.45	2,378.80	1,975.56	2,474.85	2,073.36
f. Research & Development Expenses	706.33	524.89	2,488.37	2,026.45	2,488.37	2,026.45
g. Other expenditure	2,830.27	1,914.94	11,108.47	9,650.55	14,704.38	12,274.88
h. Total	**10,441.19**	**9,314.29**	**39,138.48**	**33,020.80**	**43,331.37**	**35,131.47**
3. Profit from operations before Other Income, Interest & Exceptional Items	**2,143.58**	**1,497.24**	**6,576.08**	**5,168.95**	**7,155.80**	**5,782.78**
4. Other Income	40.24	40.36	164.96	104.45	282.95	108.51
5. Profit before Interest & Exceptional items	**2,183.82**	**1,537.60**	**6,741.04**	**5,273.40**	**7,438.75**	**5,891.29**
6. Interest	349.56	383.81	1,565.82	1,907.29	1,782.11	2,015.20
7. Profit after Interest but before Exceptional items	**1,834.26**	**1,153.79**	**5,175.22**	**3,366.11**	**5,656.64**	**3,876.09**
8. Exceptional items	-	-	-	-	-	-
9. Profit from Ordinary Activities before tax	**1,834.26**	**1,153.79**	**5,175.22**	**3,366.11**	**5,656.64**	**3,876.09**
10. Tax Expense	87.62	149.75	530.68	512.34	585.38	475.72
11. Net Profit from Ordinary Activities after tax	**1,746.64**	**1,004.04**	**4,644.54**	**2,853.77**	**5,071.26**	**3,400.37**
12. Extraordinary items (net of tax expense)	-	-	-	-	-	-
13. Net Profit for the period	**1,746.64**	**1,004.04**	**4,644.54**	**2,853.77**	**5,071.26**	**3,400.37**
14. Paid-up Equity Share Capital (Face value of ₹10/- each)	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61
15. Reserve excluding Revaluation Reserve	NA	NA	20,375.21	16,411.07	21,703.49	17,312.63
16. Earnings Per Share (EPS)						
Basic and diluted (not annualised) - ₹	14.92	8.58	39.67	24.37	43.31	29.04
17. Public Shareholding						
- Number of shares	3,884,879	3,884,879	3,884,879	3,884,879	3,884,879	3,884,879
- Percentage of shareholding	33.18%	33.18%	33.18%	33.18%	33.18%	33.18%
18. Promoters and promoter group shareholding						
a) Pledged/Encumbered						
- Number of shares	200,000	200,000	200,000	200,000	200,000	200,000
- Percentage of total promoter's holding	2.56%	2.56%	2.56%	2.56%	2.56%	2.56%
- Percentage of total share capital of company	1.71%	1.71%	1.71%	1.71%	1.71%	1.71%
b) Non-encumbered						
- Number of shares	7,623,621	7,623,621	7,623,621	7,623,621	7,623,621	7,623,621
- Percentage of total promoter's holding	97.44%	97.44%	97.44%	97.44%	97.44%	97.44%
- Percentage of total share capital of company	65.11%	65.11%	65.11%	65.11%	65.11%	65.11%

Statement of Assets & Liabilities					
SHAREHOLDERS FUND					
(a) Capital	1,179.61	1,179.61	1,179.61	1,179.61	
(b) Reserves and Surplus	20,375.21	16,411.07	21,703.49	17,312.63	
LOAN FUNDS	15,827.83	20,329.09	19,063.03	22,796.33	
DEFERRED TAX LIABILITY	1,092.09	580.09	1,092.09	526.90	
Total	38,474.74	38,499.86	43,038.22	41,815.47	
FIXED ASSETS	22,340.51	20,784.29	23,124.77	21,545.07	
INVESTMENTS	1,705.04	1,705.14	846.42	846.52	
CURRENT ASSETS, LOANS AND ADVANCES					
(a) Inventories	9,611.98	10,516.13	11,312.07	11,962.47	
(b) Sundry Debtors	7,576.43	8,550.41	10,398.19	9,672.44	
(c) Cash and Bank balances	1,253.56	523.39	1,476.05	1,483.86	
(d) Loans and Advances	4,803.26	3,848.44	5,059.22	3,998.79	
Sub Total	23,245.23	23,438.37	28,245.53	27,117.56	
Less: Current Liabilities and Provisions					
(a) Liabilities	7,729.14	6,666.31	8,091.60	6,932.05	
(b) Provisions	1,086.90	761.63	1,086.90	761.63	
Sub Total	8,816.04	7,427.94	9,178.50	7,693.68	
Net Current Assets	14,429.19	16,010.43	19,067.03	19,423.88	
Total	38,474.74	38,499.86	43,038.22	41,815.47	

Notes :

1. Above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 30th April, 2011.
2. Board of Directors have recommended dividend of ₹5/- per share for the year ended March 31, 2011.
3. The company has one segment of activity namely, pharmaceuticals.
4. Investor's Complaints status for the quarter - Opening - 0, Received - 8, Resolved - 8, Closing - 0.
5. Previous period's figures have been regrouped wherever necessary.

AJANTA PHARMA LIMITED MUMBAI

By order of the Board
For Ajanta Pharma Ltd.

Purushottam B. Agrawal
Vice Chairman

Mumbai, April 30, 2011